Objective: To report a case of chlordiazepoxide-associated Stevens-Johnson syndrome (SJS). Case Summary: This case provides insight into a serious adverse drug reaction secondary to a drug not commonly associated with SJS. A 29-year-old female presented with a 4-day history of rash and pruritus. The rash started on her arms and spread all over her body. The patient was started on chlordiazepoxide 3½ weeks ago. On examination, there were multiple, raised, round erythematous lesions in various stages of healing. Skin erosions were noted on her lips and buccal mucosa. However, the rash did not involve the conjunctiva, inner ears, or genitalia. The patient was discharged home with a follow-up appointment with dermatology and instructions to discontinue chlordiazepoxide. Two days after her initial presentation, the patient’s rash spread to her eyes and genitalia. A painful, white film developed on her tongue, and she was unable to tolerate oral intake. She was emergently sent back to hospital and transferred to a Burn Unit. The biopsy report revealed full-thickness necrotizing keratinocytes in the epidermis consistent with SJS. Discussion: To our knowledge, there is only one other case report of chlordiazepoxide-associated SJS. Chlordiazepoxide is thought to be the cause of this patient’s biopsy-confirmed SJS and overall presentation. SJS is a rare but serious condition that is usually a result of drug exposure. Conclusions: The close temporal relationship between chlordiazepoxide initiation and onset of SJS provides a convincing theory as to the etiology of SJS in our patient.
BulisaniACPSanchesGDGuimarãesHPLopesRDVendrameLSLopesAC. Síndrome de Stevens-Johnson e necrólise epidérmica tóxica em medicina intensiva. Rev Bras Ter Intensiva. 2006;18:292-297.
2.
Dodiuk-GadRPLawsPMShearNH.Epidemiology of severe drug hypersensitivity. Semin Cutan Med Surg. 2014;33(1):2-9.
3.
NaldiLCrottiS.Epidemiology of cutaneous drug-induced reactions. G Ital Dermatol Venereol. 2014;149:207-218.
4.
SchwartzRAMcDonoughPHLeeBW.Toxic epidermal necrolysis: part I. Introduction, history, classification, clinical features, systemic manifestations, etiology, and immunopathogenesis. J Am Acad Dermatol. 2013;69:173.e1-e13. DOI:10.1016/j.jaad.2013.05.003.
5.
OliveiraASanchesMSeloresM.Stevens-Johnson syndrome and toxic epidermal necrolysis [in Portuguese]. Acta Med Port. 2011;24(suppl 4):995-1002.
6.
HuangPTsaiW.Chlordiazepoxide-induced Stevens Johnson syndrome. J Chin Med Assoc. 2005;68:276-278. doi:10.1016/S1726-4901(09)70150-9.
LoncarCFranićTBilusićM.Toxic epidermal necrolysis caused by flurazepam?Psychiatr Danub. 2005;17:236-239.
10.
US Food and Drug Administration. FDA drug safety communication: FDA warns of serious skin reactions with the anti-seizure drug Onfi (clobazam) and has approved label changes. https://www.fda.gov/Drugs/DrugSafety/ucm377204.htm. Updated January 15, 2016. Accessed May 24, 2017.
11.
SánchezIGarcía-AbujetaJLFernándezLet al. Stevens-Johnson syndrome from tetrazepam. Allergol Immunopathol. 1998;26:55-57.
12.
LagnaouiRRamanampamonjyRJulliacBHaramburuFTicolatR.Fatal toxic epidermal necrolysis associated with tetrazepam. Therapie. 2001;56:187-188.
13.
DelesalleFCarpentierOGuatierSDelaporteE.Toxic epidermal necrolysis caused by tetrazepam. Int J Dermatol. 2006;45:480. doi:10.1111/j.1365-4632.2006.02654.x.
Martin-MerinoEde AbajoFJGilM.Risk of toxic epidermal necrolysis and Stevens-Johnson syndrome associated with benzodiazepines: a population-based cohort study. Eur J Clin Pharmacol. 2015;71:759-766. doi:10.1007/s00228-015-1850-y.
16.
NaranjoCABustoUSellersEMet al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30:239-245.
17.
SassolasBHaddadCMockenhauptMet al. ALDEN, an algorithm for assessment of drug causality in Stevens-Johnson syndrome and toxic epidermal necrolysis: comparison with case-control analysis. Clin Pharmacol Ther. 2010;88:60-68. doi:10.1038/clpt.2009.252.
